Johnson D A
J Clin Psychiatry. 1985 May;46(5 Pt 2):6-15.
In neuroleptic maintenance therapy, first-illness schizophrenic patients should be prescribed continuing medication for at least one year. In the management of chronic schizophrenic patients following relapse, neuroleptic medication in standard oral doses or depot injections is recommended for periods in excess of 5 years to reduce the risk of relapse. Results are summarized from studies regarding drug therapy in conjunction with psychotherapeutic factors and family environment, the efficacy of lower dosage, benefit/risk ratios, and the advantages of long-term neuroleptic maintenance. The relationships of neuroleptic dose to plasma level and to therapeutic response are considered, as well as the implications of polypharmacy (e.g., use of anticholinergic drugs with neuroleptics).
在抗精神病药物维持治疗中，首发精神分裂症患者应持续用药至少一年。在慢性精神分裂症患者复发后的管理中，建议使用标准口服剂量的抗精神病药物或长效注射剂超过5年，以降低复发风险。总结了关于药物治疗结合心理治疗因素和家庭环境、低剂量疗效、获益/风险比以及长期抗精神病药物维持治疗优势的研究结果。考虑了抗精神病药物剂量与血浆水平及治疗反应的关系，以及联合用药（如抗胆碱能药物与抗精神病药物联用）的影响。
